THE first head-to-head comparison of the efficacy of Mounjaro (tirzepatide) and Wegovy (semaglutide) in adults with obesity or who are overweight with weight-related comorbidities has found in favour of Mounjaro, reports Mounjaro manufacturer Eli Lilly.
The top-line results, which have not yet been published in a peer-reviewed journal, showed that Mounjaro delivered a clinically meaningful benefit and statistically significant weight loss, with patients experiencing a 47% greater relative weight loss compared to Wegovy at 72 weeks.
The SURMOUNT-5 trial included around 750 adults with obesity, or who are overweight without diabetes but with at least one of the following comorbidities: hypertension, dyslipidaemia, obstructive sleep apnea or cardiovascular disease.
The trial found that, on average, participants using Mounjaro lost 20.2% (22.8kg) of body weight and participants on Wegovy lost 13.7% (15kg) over the 72 weeks.
Kelly Frankel of Eli Lilly Australia and New Zealand said, "The dual action of Mounjaro on GIP and GLP-1 has been shown superior in terms of weight loss to sole GLP-1 inhibition in this important head-to-head trial".
"These new data add to the body of evidence that Mounjaro is superior among its respective indications," Kelly added, with an earlier trial having demonstrated superior HbA1c reduction for those treated with Mounjaro, compared to semaglutide (Ozempic), in patients who had type 2 diabetes.
Lilly dropped the recommended retail price of Mounjaro last week to $285 (PD 02 Dec), and Frankel said, "we will continue to work with all stakeholders to secure a path to affordable and equitable access to Mounjaro in Australia".
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Dec 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Dec 24
